Clinical Trial: An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma

U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07344818) titled 'An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma' on Jan. 07.

Brief Summary: To observe the efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory or relapsed aggressive B-cell lymphoma

Study Start Date: Jan. 07

Study Type: INTERVENTIONAL

Condition: R/R Aggressive B-cell Lymphoma

Intervention: BIOLOGICAL: CAR-T cell therapy

autologous CD19+CD20 dual CAR-T cells, single injection

Recruitment Status: RECRUITING

Sponsor: Peking University People's Hospital

Information provided by (Responsible ...